Phathom Pharmaceuticals, Inc. PHAT
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a GI/hepatology drug developer. Its lead program, VOQUEZNA (vonoprazan), is in Phase 2 for Erosive GERD, Non-Erosive GERD heartburn, H. pylori infection. Its next catalyst on record is Vonoprazan (EoE): Topline results from 12-week blinded treatment portion of Phase 2 EoE trial (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Vonoprazan (EoE) — Topline results from 12-week blinded treatment portion of Phase 2 EoE trial (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VOQUEZNA tablets (vonoprazan) | Erosive GERD, Non-Erosive GERD heartburn, H. pylori | small molecule | Approved |
| VOQUEZNA DUAL PAK | H. pylori infection | small molecule | Approved |
| VOQUEZNA TRIPLE PAK | H. pylori infection | small molecule | Approved |
| Vonoprazan (EoE) | Eosinophilic esophagitis (Phase 2, enrollment complete) | small molecule | Phase 2 |
Recent results and decisions
- Oct 23, 2026n/a BDR Pharmaceuticals filed suit against the FDA challenging the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets through May 3, 2032.
BDR alleges that FDA has improperly applied the GAIN Act to extend Phathom's New Chemical Entity (NCE) exclusivity for VOQUEZNA (vonoprazan fumarate) tablets.
Filing - Sep 29, 2026started Patient screening initiated in registrational Phase 3 pHalcon-NERD-302 of as-needed vonoprazan in non-erosive GERD (~500 adults, ~80 US sites, 24-week treatment).
Phathom announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive Gastroesophageal Reflux Disease
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.